fbpx

News

Lundbeckfonden Ventures News

CAMBRIDGE, Mass., Jan. 31, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that on January 31, 2020 the Compensation Committee of Spero’s Board of Directors granted non-qualified stock option awards...
$30 Million fully backstopped rights offering will be available to all stockholders of record on February 10, 2020 CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced its...
Cambridge, UK and Indianapolis, US – 24 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, has been awarded BEL Small Company of the Year 2019 by Euronext Brussels at its annual New Year’s Ceremony held in...
Copenhagen, Denmark, 17 January 2020 Asahi Kasei Pharma Denmark A/S Announces the Final Result of the Voluntary Public Tender Offer Asahi Kasei Pharma Denmark A/S, which on 15 January 2020 announced the preliminary result of the voluntary public tender offer for the shares and warrants in Veloxis Pharmaceuticals A/S, today announces the final result of...
Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialisation of new nausea and vomiting treatments for surgical and cancer patients, announces that application has been made to Euronext Brussels for the admission of the 8,994,667 Ordinary Shares of...
First indication of human safety and pharmacokinetic profiles for SPR206 supports advancement of program to clinical pharmacology studies planned to initiate in the second half of 2020 CAMBRIDGE, Mass., Jan. 13, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug...
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014. Cambridge, UK and Indianapolis, US – 13 January 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Company”, the “Group”), (EURONEXT: ACPH), a pharmaceutical company developing and commercialising hospital products for US and international markets, announces a...
Acacia Pharma has in-licensed exclusive US rights to ultra-short-acting sedative, ByFavo™ (remimazolam) from Cosmo adding to its portfolio of near-market products Cosmo will make a €10 million equity investment in Acacia Pharma and provide a new €35 million loan facility to support commercial activities This announcement contains inside information for the purposes of Article 7...
Former Celgene Business Development Head Brings Entrepreneurial Expertise and Life Science Business Leadership CAMBRIDGE, Mass.–(BUSINESS WIRE)– Aura Biosciences, a clinical-stage biopharmaceutical company developing a new class of tumor targeted therapies for initial application in primary tumors such as ocular and bladder cancers, today announced the appointment of George Golumbeski, Ph.D., as Chairman of its Board...
1 2 3 4 5 64

Lundbeckfonden Ventures

News

Horizon Therapeutics plc Acquires Curzion Pharmaceuticals, Inc. and Its LPAR1 Antagonist Product Candidate to Expand Development-Stage Pipeline
3. April 2020
Acacia Pharma Group PLC – Publication of Prospectus
25. March 2020
Acacia Pharma Group PLC – Forthcoming 2020 Annual General Meeting – Change of Venue and Proxy Forms
23. March 2020